Research Analysts Offer Predictions for JANX FY2026 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for Janux Therapeutics in a research report issued on Tuesday, December 3rd. Leerink Partnrs analyst J. La. Rosa now expects that the company will earn ($6.13) per share for the year, down from their prior forecast of ($6.12). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ FY2027 earnings at ($5.92) EPS and FY2028 earnings at ($4.25) EPS.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year.

Other research analysts have also recently issued reports about the company. Scotiabank upped their price objective on Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research report on Wednesday. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday. Leerink Partners increased their price target on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday. Stifel Nicolaus boosted their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $79.90.

Janux Therapeutics Stock Down 0.8 %

Shares of Janux Therapeutics stock opened at $66.30 on Thursday. Janux Therapeutics has a 52-week low of $7.79 and a 52-week high of $71.71. The company has a market capitalization of $3.48 billion, a P/E ratio of -56.67 and a beta of 3.29. The company has a 50 day moving average of $50.21 and a 200 day moving average of $45.96.

Institutional Trading of Janux Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its holdings in shares of Janux Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares during the period. Janus Henderson Group PLC increased its position in Janux Therapeutics by 40.0% during the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after purchasing an additional 721,563 shares in the last quarter. Vanguard Group Inc. raised its holdings in Janux Therapeutics by 38.6% in the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the period. Logos Global Management LP lifted its position in Janux Therapeutics by 400.0% during the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock valued at $31,418,000 after buying an additional 600,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares in the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 50,000 shares of the stock in a transaction on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the sale, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. This represents a 12.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 352,245 shares of company stock worth $17,032,336 over the last 90 days. Company insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.